SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Schedule of Revenue by Payor Class

Revenue by payor class as a percentage of total net service revenue is as follows:

	For the Three-Month Periods Ended September 30				For the Nine-Month Periods Ended September 30
	2019		2018		2019		2018
Home Health:
Medicare	43	%	50	%	44	%	51	%
Non-Medicare - Episodic-based	9	%	9	%	9	%	8	%
Non-Medicare - Non-episodic based	11	%	12	%	12	%	12	%
Hospice (1):
Medicare	31	%	23	%	30	%	23	%
Non-Medicare	2	%	1	%	1	%	1	%
Personal Care	4	%	5	%	4	%	5	%
	100	%	100	%	100	%	100	%
(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):

	Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2019		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	240.6	$	—	$	236.0	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):

	For the Three- Month Periods Ended September 30,		For the Nine- Month Periods Ended September 30,
	2019	2018	2019	2018
Weighted average number of shares outstanding - basic	32,211	31,815	32,096	33,075
Effect of dilutive securities:
Stock options	532	561	543	464
Non-vested stock and stock units	259	315	305	313
Weighted average number of shares outstanding - diluted	33,002	32,691	32,944	33,852
Anti-dilutive securities	133	51	154	76